Overview
HAIXI PHARMA (2637)
Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs f...
- Open
- 153.500
- High
- 155.600
- Low
- 140.200
- Prev. Close
- 156.000
- Volume
- 85.85K
- Turnover
- 12.54M
- Avg Price
- 146.042
- Bid/Ask Ratio
- 33.33%
- Amplitude
- 9.87%
- 52wk High
- 302.400
- Volume Ratio
- 0.55
- Turnover Ratio
- 0.11%
- 52wk Low
- 121.600
- HK Mkt Cap
- 11.32B
- Market CapHKD
- 11.32B
- P/ETTM
- 65.42
- P/EDynamic
- 60.64
- P/EStatic
- --
- EPSTTM
- 2.20
- EPSDynamic
- 2.37
- EPSStatic
- --
- BVPS
- 24.42
- P/B
- 5.89
- HK Shares
- 78.71M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 78.71M
- Min lot size
- 50
- Currency
- HKD
HAIXI PHARMA Analyst Rating
View moreForecast & Rating
Oct 8, 2026- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 2
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Haixi Pharma reversed early gains and closed at HK$144.1, down 7.6% from HK$156, after spiking to HK$155.7 at 09:33 and sliding to HK$140.6 at 15:18. The pullback followed a prior one-day 12% surge and coincided with a profit slowdown: Q2 revenue rose 9.46% to HK$179.97 million, but net profit fell 20.75% to HK$46.81 million and EPS dropped 32.16% to HK$0.5947, so top-line growth did not translate into bottom-line growth. The close sits below MA20 at HK$146.98 and MA60 at HK$169.66, 52.35% below the 52-week high of HK$302.4, though it remains up 9.25% year-to-date, with a PE of 65.55x. Turnover was HK$12.64 million, indicating the selling was not accompanied by heavy volume expansion. Still, Huafu Securities and CMB International had both maintained their prior ratings, and an IND for HX9428 Phase IIa in diabetic macular edema has been submitted, leaving clinical progress as a variable.
- Nov, 6
Shares of 2637.HK closed at HK$152.20, up 1.81% from the prior close of HK$149.50, in a spike-and-fade session driven by controlling shareholders' voluntary 12-month no-reduction undertaking: the stock ran to HK$164.00 at 14:00 BJ before surrendering most of the gain, a swing of more than 10% from the 09:52 morning low of HK$148.50, on light turnover of HK$22.28 million and a 0.18% turnover rate. Fundamentals cut against the tape — Q2 2026 revenue rose 9.46% year on year to HK$179.97 million, yet net profit fell 20.75% to HK$46.81 million and EPS dropped 32.16% to HK$0.5947, leaving a 26.01% net margin against 69.24x PE and 6.23x PB. The price sits above the HK$148.20 MA20 but below the HK$174.98 MA60, up 15.39% year to date while still 49.67% below the HK$302.40 52-week high. Though the company also disclosed H-share purchases under its share award scheme, that support sits alongside shrinking earnings.
- Nov, 5
Haixi Pharma dipped to HK$147.40 at the open, spiked to an intraday HK$155.50, then gave the gains back and slid from HK$151.90 through the afternoon to close at HK$149.50, up 1.08%. The early bid traced to HX9428: 24-week Phase I treatment data in nAMD have been read out, Phase II dose expansion has interim data, and a DME Phase IIa trial application has been filed, while the company bought H shares under its share award scheme and China Merchants Securities International kept a Buy rating. Revenue and profit diverged, with Q2 revenue of HK$179.97m up 9.46% year on year while net profit fell 20.75% to HK$46.81m. At HK$149.50 the stock sits above its MA20 of HK$148.34 but below MA60 of HK$175.72, 50.56% under the 52-week high of HK$302.40 yet up 13.34% year to date, on a PE of 68.01x. Trading was thin though, with only 51,500 shares changing hands and a 0.07% turnover rate, leaving little support after the morning spike.
- Oct, 28
Haixi Pharma rallied straight through the afternoon to close at HK$148.50, up 5.77%, tracing a dip-then-rally shape: it sank to HK$137.60 after the 09:43 morning low and then printed the HK$148.50 intraday high at 13:27 BJ, driven by progress on HX9428 — the oral nAMD candidate has completed 24-week Phase I data observation and produced interim Phase II dose-expansion data, with a DME Phase IIa trial application already filed, while Huafu Securities, CMB International and SDIC Securities each carried Buy ratings. Fundamentals cut the other way: Q2 2026 revenue rose 9.46% YoY to HK$179.97m, yet net profit fell 20.75% to HK$46.81m and EPS dropped 32.16% to HK$0.5947. The stock is up 12.59% YTD but sits 50.89% below its 52-week high of HK$302.40 and beneath both the MA20 of HK$154.86 and MA60 of HK$181.19, at a PE of 67.56x. Though volume of just 35,700 shares and a 0.05% turnover rate leave the tape thin.
- Oct, 21
Haixi Pharma gapped up to a session high of HK$154.6 at the open before a steady one-way retreat, touching HK$140.0 at 15:54 BJ time and closing at HK$141.5, down 6.23% on roughly HK$36.4m turnover. The drop followed a 6.87% weekly gain built on HX9428 oral nAMD readouts — 24-week Phase I data and interim Phase II dose-expansion results — plus H-share purchases under the share award scheme, with China Merchants Securities and Huafu Securities retaining buy ratings, so today's slide looks like profit-taking on that run. Fundamentals are split: Q2 2026 revenue rose 9.46% yoy to HK$180.0m, yet net profit fell 20.75% to HK$46.8m and EPS dropped 32.16% to HK$0.5947, leaving PE at 64.37x and PB at 5.79x. The stock is up only 7.28% YTD but sits 53.21% below its 27 April 52-week high of HK$302.4 and beneath both MA20 (HK$162.25) and MA60 (HK$183.53). Though further HX9428 clinical progress remains the swing factor.
News
Market Movers · Haixi Pharma falls nearly 6%
Market Movers · Haixi Pharma surges 12% in Hong Kong trading
Global Report · Hong Kong Hospital Stocks Have a New Script: Buybacks and Exits
Global Report · A USD 90 Million Upfront Anchors Hong Kong Biotech's December Rush
Weekly Review · Weekly Recap | HAIXI PHARMA +6.87%, most brokers rate it buy
Tip Ranks · Huafu Securities Reaffirms Their Buy Rating on Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)
